Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser, Stefan; Steg, Philippe; Oldgren, Jonas; Nickenig, Georg; Kiss, Robert; Ongen, Zeki; Navarro Estrada, Jose; Ophuis, Ton; Lip, Gregory; Nordaby, Matias; Kleine, Eva; ten Berg, Jurrien; Bhatt, Deepak; Cannon, Christopher

doi:10.1016/j.jcin.2019.05.050

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Atıf İçin Kopyala

Hohnloser S. H. , Steg P. G. , Oldgren J., Nickenig G., Kiss R. G. , Ongen Z., ...Daha Fazla

JACC-CARDIOVASCULAR INTERVENTIONS, cilt.12, sa.16, ss.1553-1561, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 12 Konu: 16
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jcin.2019.05.050
Dergi Adı: JACC-CARDIOVASCULAR INTERVENTIONS
Sayfa Sayıları: ss.1553-1561

Özet

OBJECTIVES The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.